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and Common Terminology Criteria for Adverse Events (CTCAE) liver-related
laboratory tests and categories. Those with grade ≥3 ALT/AST elevation were
evaluated for rate of resolution to grade ≤1 ALT/AST, and recurrence of the
event at any time on study. Patients were grouped by use of IDELA alone or
as part of a combination regimen.
Results: Among patients with any disease type or regimen (N=1073), the inci-
dence of any grade ALT/AST elevation was 51%, and the incidence of grade
≥3 ALT/AST elevation was 14% (Table). Of patients with transaminase eleva-
tion, 73% (398/543) experienced grade 1 or grade 2 events. The incidences of
grade ≥3 ALT/AST elevations, and outcomes for patients with grade ≥3
ALT/AST elevation (Table) were comparable whether IDELA was used alone
or in combination. 92% of patients with grade ≥3 ALT/AST elevation were man-
aged with dose interruption and achieved resolution to grade ≤1. The majority
(69%) of patients with subsequent IDELA rechallenge experienced no recur-
rence of the event; of events that did recur, the vast majority (94%) resolved in
the analysis time period.
Summary/Conclusions: These data support the management of ALT/AST
elevation with IDELA using dose interruption at grade 3 with reintroduction
after resolution at the discretion of the treating physician. Studies Included in
this Analysis: 101-02: NCT00710528; 101-07: NCT01088048; 101-08:
NCT01203930; 101-09: NCT01282424; 101-10: NCT01306643; 101-11:
NCT01393106; 101-99 (extension): NCT01090414; GS-US-312-0116:
NCT01539512; GS-US-312-0117 (extension): NCT01539291; GS-US-312-
0119: NCT01659021
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Background: Some chronic myeloid leukaemia (CML) patients with prolonged
and deep molecular remissions on tyrosine kinase inhibitor (TKI) therapy can
discontinue treatment. However, study of this has been restricted to patients
in stable MR4 (BCR-ABL1<0.01%), and it is not known whether some patients
in stable major molecular response (MR3; BCR-ABL<0.1%) but not MR4 can
discontinue treatment. In addition, it is plausible that while some patients might
not be able to completely discontinue TKI therapy, they may be able to maintain
good molecular remissions on TKI doses that are less than standard, with con-
current improvement in any TKI-related adverse events; this has not been pre-
viously investigated.
Aims: The British DESTINY study is examining the safety and efficacy of ini-
tially de-escalating therapy to half the standard TKI dose (i.e. imatinib 200mg
daily, nilotinib 200mg twice daily, or dasatinib 50mg daily) for 12 months, then
stopping altogether.
Methods: Entrants must be in stable MR3 or better, on all PCR results (mini-
mum of 3) in the preceding 12 months, and must have received TKI for at least
3 years, and not switched TKI (except that a single switch was permitted if
solely due to intolerance). The primary endpoint is loss of MR3; monthly molec-
ular monitoring is carried out centrally.
Results: During 16 months recruitment to April 2015, 174 patients (male 98;
female 76) were recruited after giving informed consent by 20 sites. At entry,
125 (72%) were in MR4 and 49 (28%) in MR3 but not MR4; 148 were receiving
imatinib, 16 on nilotinib and 10 on dasatinib. During 12 months of de-escalation
in the first 100 patients, no deaths, disease progressions or losses of cytoge-
netic response have been seen, though 7 serious adverse events have
occurred (6 Grade 3+), all unrelated to TKI. Thirteen patients reported 14 new
events of musculoskeletal disorders since decreasing TKI therapy (all Grade
1), comprising pain, stiffness or cramps in the joints, legs, chest, neck and/or
back (13) with one additional event of arthritis. Individual side effects (lethargy,
diarrhoea, rash, nausea, periorbital oedema, hair thinning) all improve in the
first 1-2 months of de-escalation but not significantly thereafter, though the
FACT-BRM or EQ-5D Quality of Life data are already optimal at trial entry, sug-
gesting that TKI side effects in entrants do not impact Quality of Life. During
the de-escalation phase in the first 100 patients there have been 7 molecular
relapses (defined as loss of MR3 on 2 consecutive samples), occurring during
the second (1 case), third (2), seventh (1) and eighth (3) month of de-escalation.
Four of these were in the 31 patients in MR3 but not MR4 at trial entry, giving
a relapse rate of 12.9%; similarly 3 of 69 patients (4.3%) relapsed in the ‘MR4
at entry’ group. No relapses have occurred in the quartile with the shortest
duration of prior TKI treatment (less than 4.8 years), while 3 of the 7 relapses
have occurred in the quartile with the longest pre-entry TKI treatment (>10.2
years). All 7 patients have regained at least MR3 within 4 months of resumption
of standard dose TKI. Overall, 26 (84%) ‘MR3 but not MR4’ and 64 (93%) ‘MR4
at entry’ patients have proceeded to the stopping phase.
Summary/Conclusions: In this first DESTINY trial report focussed on de-
escalation, halving the standard TKI dose for 12 months in CML patients in at
least MR3 appears safe, does not compromise disease control, and is associ-
ated with a rapid improvement in side effects. Mild musculoskeletal symptoms
may occur in about 13% of patients.
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